Search
Congratulations to Dr Lea-Ann Kirkham - one of just 10 recipients from around the world to receive a prestigious Robert Austrian Award at the International Symposium on Pneumococci and Pneumococcal Diseases.
How protective is the whooping cough vaccine? Vaccination and allergy Even though Australia has high vaccination rates against whooping cough, we
Find out more about the scholarship opportunities at the Wesfarmers Centre, including Training Scholarships and Higher Degree by Research Scholarships.
The Wesfarmers Centre is pleased to announce the successful recipients for the 2018 Round 2 Seed Funding Grants. The Wesfarmers Centre Scientific
The Wesfarmers Centre is pleased to announce the successful applications for the 2018 Round 1 Wesfarmers Centre Seed Funding. The Wesfarmers Centre
The Wesfarmers Centre is pleased to announce the 4 successful applications for the 2016 Round 1 Wesfarmers Centre Seed Funding.
Wesfarmers Centre of Vaccines & Infectious Diseases resources
Respiratory syncytial virus (RSV) is a significant cause of respiratory infections in young children. Since 2021, RSV has been a notifiable disease in Australia. However, current surveillance systems focus on hospitalised RSV, with limited surveillance at a community level through primary care clinics. This approach only captures RSV requiring hospitalisation. Less severe illnesses, while not captured, may have significant social and economic impacts including the associated cost of care and absenteeism. The aim of this study is to establish an understanding of the broader burden of RSV in young children in a community setting.
Protection of newborns from infection can be achieved through maternal or vaccine-induced antibodies, but the factors influencing vaccine protection (correlate of protection) and subsequent infant immunity remain insufficiently understood. Further investigation is essential to optimize early-life vaccination strategies.
Pneumococcal conjugate vaccine (PCV) prevents pneumococcal disease and pneumonia, but indirect effects are poorly understood in low-coverage, high-burden settings like Papua New Guinea (PNG). PNG introduced 13-valent PCV (PCV13) in 2014. We aimed to assess direct and indirect effectiveness of PCV13 against vaccine-type pneumococcal carriage among children with pneumonia or suspected meningitis in PNG